Synchronous primary tumors amd distant metastasis detected on F-FDG PET in patients with head and neck carcinoma.

Objectives: F-FDG PET/CT has been used to characterize the primary lesion and staging in head and neck cancers (HNC). However, prior studies for detecting distant metastasis and synchronous tumors are sparse, especially in Indian context. To investigate the frequency and distribution of head and neck carcinomas, distant metastases and synchronous malignancies detected in HNC in a north Indian population.

First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [Lu]Lu-DOTA.SA.FAPi and [Lu]Lu-DOTAGA.(SA.FAPi).

Recently, great interest has been gained regarding fibroblast activation protein (FAP) as an excellent target for theranostics. Several FAP inhibitor molecules such as [Ga]Ga-labelled FAPI-02, 04, 46, and DOTA.SA.

Novel Fibroblast Activation Protein Inhibitor-Based Targeted Theranostics for Radioiodine-Refractory Differentiated Thyroid Cancer Patients: A Pilot Study.

This exploratory study was meant to assess clinical and safety data with a novel fibroblast activation protein inhibitor-based targeted theranostics as a salvage treatment option in radioiodine-refractory differentiated thyroid cancer (RR-DTC) patients who had progressed on tyrosine kinase inhibitors. Patients with metastatic RR-DTC who progressed on sorafenib/lenvatinib were prospectively recruited. If [Ga]Ga-DOTA.

Biodistribution, pharmacokinetics, dosimetry of [Ga]Ga-DOTA.SA.FAPi, and the head-to-head comparison with [F]F-FDG PET/CT in patients with various cancers.

Purpose: [Ga]Ga-labeled fibroblast activation protein inhibitors ([Ga]Ga-FAPi) have shown promising preclinical and clinical results in PET imaging. The present study aimed to evaluate the biodistribution, pharmacokinetics, and dosimetry of [Ga]Ga-DOTA.SA.